Altamira Therapeutics Ltd. (CYTO) Financials

NASDAQ Currency in USD Disclaimer

$0.30

south_east -$0 (0%)
Day's range
$0.3
Day's range
$0.42

CYTO Income statement / Annual

Last year (2023), Altamira Therapeutics Ltd.'s total revenue was $0.00, a decrease of 100.00% from the previous year. In 2023, Altamira Therapeutics Ltd.'s net income was -$7.27 M. See Altamira Therapeutics Ltd.�s key income statements, including revenue, expenses, profit, and income.

Period FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015 FY-2014
Period Ended 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Operating Revenue $0.00 $305,616.00 $63,882.00 $174,475.00 -$56,000.00 $1.27 M $322,000.00 -$414,000.00 -$67,000.00 $3.01 M
Cost of Revenue $0.00 $1.44 M $2.24 M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Gross Profit $0.00 -$1.14 M -$2.18 M $174,475.00 -$56,000.00 $1.27 M $322,000.00 -$414,000.00 -$67,000.00 $3.01 M
Gross Profit Ratio 0 -3.72 -34.07 1 1 1 1 1 1 1
Research and Development Expenses $3.04 M $19.68 M $8.94 M $2.86 M $3.33 M $6.69 M $19.21 M $24.78 M $26.54 M $17.70 M
General & Administrative Expenses $3.09 M $3.52 M $4.90 M $2.59 M $3.93 M $4.26 M $5.15 M $5.41 M $4.34 M $4.49 M
Selling & Marketing Expenses $15,348.00 $2.38 M $1.50 M $95,663.00 $113,959.00 $43,816.00 $199,484.00 $45,649.00 $72,562.00 $237,720.00
Selling, General & Administrative Expenses $3.12 M $5.90 M $6.39 M $2.59 M $3.93 M $4.26 M $5.15 M $5.41 M $4.34 M $4.49 M
Other Expenses $0.00 -$586,730.00 -$409,929.00 $0.00 $0.00 $215,720.00 $87,593.00 $34,055.00 $62,198.00 $73,434.00
Operating Expenses $6.54 M $24.99 M $14.92 M $5.46 M $7.26 M $10.95 M $24.36 M $30.22 M $30.88 M $22.19 M
Cost And Expenses $6.54 M $26.44 M $17.16 M $5.46 M $7.26 M $10.95 M $24.36 M $30.22 M $30.88 M $22.19 M
Interest Income $730,195.00 $969.00 $3,219.00 $258.00 $17,882.00 $0.00 $53,570.00 $67,565.00 $37,000.00 $52,133.00
Interest Expense $0.00 $911,869.00 $189,695.00 $135,151.00 $28,628.00 $1.07 M $1.64 M $828,547.00 $8,000.00 $49,635.00
Depreciation & Amortization $5.92 M $118,887.00 $76,357.00 $20,036.00 $30,823.00 $72,713.00 $122,784.00 $97,600.00 $92,777.00 $73,984.00
EBITDA -$1.35 M -$17.64 M -$6.72 M -$5.26 M -$7.24 M -$10.95 M -$24.31 M -$30.06 M -$30.84 M -$22.19 M
EBITDA Ratio 0 -85.12 -266.43 -30.28 129.31 -8.65 -75.49 72.6 460.31 -7.38
Operating Income Ratio 0 -85.51 -267.68 -30.28 129.63 -8.65 -75.66 73 460.87 -7.38
Total Other Income/Expenses Net -$1.35 M -$645,643.00 -$1.46 M -$2.94 M $433,406.00 -$380,101.00 -$65,996.00 -$570,031.00 $1.17 M $4.01 M
Income Before Tax -$7.27 M -$26.54 M -$17.37 M -$8.22 M -$6.83 M -$11.33 M -$24.43 M -$30.79 M -$29.71 M -$18.19 M
Income Before Tax Ratio 0 -86.84 -271.88 -47.12 121.89 -8.95 -75.86 74.38 443.36 -6.04
Income Tax Expense $0.00 -$10,329.00 $21,620.00 -$21,284.00 -$193,837.00 $162,177.00 -$17,773.00 -$131,055.00 -$84,777.00 -$892,177.00
Net Income -$7.27 M -$26.53 M -$17.39 M -$8.20 M -$6.63 M -$11.50 M -$24.41 M -$30.66 M -$29.71 M -$18.19 M
Net Income Ratio 0 -86.8 -272.22 -47 118.43 -9.08 -75.81 74.06 443.36 -6.04
EPS -14.81 -582.58 -525.13 -545.41 -455.96 -2892.03 -22322.34 -35728.56 -36790.93 -26267.51
EPS Diluted -14.8 -582.58 -525.13 -545.41 -455.96 -2892.03 -22322.34 -35728.56 -36790.93 -26267.51
Weighted Average Shares Out $491,000.00 $45,536.00 $33,116.00 $15,035.00 $14,545.00 $3,975.20 $1,093.50 $858.20 $807.40 $692.30
Weighted Average Shares Out Diluted $491,258.00 $45,536.00 $33,116.00 $15,035.00 $14,545.00 $3,975.20 $1,093.50 $858.20 $807.40 $692.30
Link